Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00084604 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 |
| clinicaltrials |
| NCT00397787 | Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00002470 | Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors | completed | Phase 2 | — | Mid-Atlantic Oncology ProgramOTHER | 1 | May 15, 2013 | clinicaltrials |
| NCT00707889 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | completed | Phase 2 | 159 | AbbVie (prior sponsor, Abbott)INDUSTRY | 14 | May 15, 2013 | clinicaltrials |
| NCT00425035 | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 | completed | Phase 2 | 115 | AmgenINDUSTRY | 0 | May 13, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00410826 | Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 2 | 204 | University of WashingtonOTHER | 1 | May 10, 2013 | clinicaltrials |
| NCT00242502 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2013 | clinicaltrials |
| NCT00003943 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00137774 | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | completed | Phase 2 | 34 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2013 | clinicaltrials |
| NCT00027872 | Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00182702 | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00494091 | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 82 | PfizerINDUSTRY | 3 | Mar 21, 2013 | clinicaltrials |
| NCT00951613 | A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 72 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00490698 | Zoledronate With Atorvastatin in Renal Cell Carcinoma | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00284154 | Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | completed | Phase 2 | 51 | SCRI Development Innovations, LLCOTHER | 1 | Mar 13, 2013 | clinicaltrials |
| NCT00028028 | CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00060307 | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00068783 | S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00096512 | S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00101114 | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00988741 | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | completed | Phase 2 | 107 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 5 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00033618 | Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT01394497 | Use of N-Acetylcysteine During Liver Procurement | completed | Phase 2 | 140 | Azienda Ospedaliera di PadovaOTHER | 1 | Feb 18, 2013 | clinicaltrials |
| NCT00619268 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma(TORAVA) | completed | Phase 2 | 160 | Centre Leon BerardOTHER | 1 | Feb 15, 2013 | clinicaltrials |
| NCT00106353 | Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 1 / Phase 2 | 71 | PfizerINDUSTRY | 7 | Feb 8, 2013 | clinicaltrials |
| NCT00557609 | Phase 2 Study in Patients With MiT Tumors | completed | Phase 2 | 47 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Feb 8, 2013 | clinicaltrials |
| NCT00251316 | Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer | completed | Phase 2 | 34 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Feb 4, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00017199 | PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT00305942 | Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 61 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00025467 | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00028834 | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00032188 | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005818 | SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00055809 | Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00031993 | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00075647 | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00103324 | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00387374 | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 0 | Jan 17, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2013source: clinicaltrials